Pancreatic mucinous cystadenoma (mucinous cystic neoplasm, MCN) is a mucin-producing cystic neoplasm of the pancreas that occurs predominantly in middle-aged women and typically arises in the body or tail of the pancreas. MCNs are characterized by an ovarian-type stroma underlying the mucinous epithelial lining. They carry malignant potential and can progress from low-grade dysplasia through high-grade dysplasia to invasive mucinous cystadenocarcinoma, with the prevalence of invasive carcinoma varying between 6% and 55% across published series. Molecularly, MCNs are driven by KRAS mutations (grade-dependent: 50% in LG, 100% in HG/INV lesions) and RNF43 loss (Wnt pathway), with progression to invasion associated with TP53, SMAD4, and CDKN2A alterations. Surgical resection is curative for non-invasive lesions.
Ask a research question about Pancreatic Mucinous Cystadenoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Pancreatic Mucinous Cystadenoma
creation_date: "2026-03-07T12:00:00Z"
updated_date: "2026-03-08T18:00:00Z"
category: Cancer
parents:
- Pancreatic Neoplasm
disease_term:
preferred_term: pancreatic mucinous cystadenoma
term:
id: MONDO:0018523
label: pancreatic mucinous cystadenoma
description: >-
Pancreatic mucinous cystadenoma (mucinous cystic neoplasm, MCN) is a mucin-producing
cystic neoplasm of the pancreas that occurs predominantly in middle-aged women and
typically arises in the body or tail of the pancreas. MCNs are characterized by an
ovarian-type stroma underlying the mucinous epithelial lining. They carry malignant
potential and can progress from low-grade dysplasia through high-grade dysplasia to
invasive mucinous cystadenocarcinoma, with the prevalence of invasive carcinoma
varying between 6% and 55% across published series. Molecularly, MCNs are
driven by KRAS mutations (grade-dependent: 50% in LG, 100% in HG/INV lesions) and RNF43 loss (Wnt pathway), with progression
to invasion associated with TP53, SMAD4, and CDKN2A alterations. Surgical
resection is curative for non-invasive lesions.
pathophysiology:
- name: Mucinous Epithelial Proliferation
description: >-
MCNs are defined by mucin-producing columnar epithelial cells lining cystic
spaces in the body or tail of the pancreas. The epithelial cells secrete
mucin, forming macrocystic lesions that do not communicate with the
pancreatic duct system.
cell_types:
- preferred_term: pancreatic ductal cell
term:
id: CL:0002079
label: pancreatic ductal cell
biological_processes:
- preferred_term: mucus secretion
term:
id: GO:0070254
label: mucus secretion
- preferred_term: epithelial cell proliferation
term:
id: GO:0050673
label: epithelial cell proliferation
locations:
- preferred_term: body of pancreas
term:
id: UBERON:0001150
label: body of pancreas
- preferred_term: tail of pancreas
term:
id: UBERON:0001151
label: tail of pancreas
evidence:
- reference: PMID:21128317
reference_title: "Management of mucinous cystic neoplasms of the pancreas."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
MCNs are pancreatic mucin-producing cysts with a distinctive ovarian-type stroma
localized in the body-tail of the gland and occurring in middle-aged females.
explanation: >-
Systematic review confirming the defining features of MCNs including
mucin-producing cysts and body-tail location.
- reference: PMID:20043327
reference_title: "Pancreatic cysts: preoperative diagnosis and clinical management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Mucinous cystic neoplasms typically arise in the body or tail of the pancreas
of middle-aged women and demonstrate a septated cyst without dilatation of the
main pancreatic duct.
explanation: >-
Describes the characteristic mucinous epithelial cystic presentation of MCNs.
downstream:
- target: Adenoma-Carcinoma Progression
description: >-
Mucinous epithelial proliferation establishes the cystic neoplasm that
can undergo stepwise dysplastic progression to invasive carcinoma.
- name: Ovarian-Type Stromal Differentiation
description: >-
MCNs are uniquely characterized by a distinctive ovarian-type stroma underlying
the mucinous epithelial lining. The stromal cells express FOXL2, estrogen
receptor, and progesterone receptor, which may drive tumor growth and explain the
strong female predominance. This aberrant ovarian-type differentiation is the
defining diagnostic criterion distinguishing MCNs from other pancreatic cystic
neoplasms.
cell_types:
- preferred_term: ovarian-type stromal cell
term:
id: CL:0002574
label: stromal cell of pancreas
evidence:
- reference: PMID:24746205
reference_title: "The expression of FOXL2 in pancreatic, hepatobiliary, and renal tumors with ovarian-type stroma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
All cases of PMC and HBC demonstrated nuclear reactivity for FOXL2 in the
subepithelial stromal cells. Ninety percent of MEST demonstrated nuclear FOXL2
positivity. Estrogen receptor nuclear positivity was demonstrated in 57% of PMC,
77% of HBC, and 80% of MEST. Progesterone receptor nuclear positivity was present
in 67% of PMC, 100% of HBC, and 90% of MEST.
explanation: >-
Demonstrates that ovarian-type stroma in pancreatic mucinous cystic neoplasms
expresses FOXL2 and hormone receptors, confirming the ovarian-type stromal
differentiation pathophysiology.
- reference: PMID:28416122
reference_title: "Patients with a resected pancreatic mucinous cystic neoplasm have a better prognosis than patients with an intraductal papillary mucinous neoplasm: A large single institution series."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Mucinous cystic neoplasms (MCNs) are rare pancreas tumors distinguished from
intraductal papillary mucinous neoplasms (IPMNs) by the presence of
ovarian-type stroma.
explanation: >-
Large clinical series confirming ovarian-type stroma as the defining
diagnostic feature distinguishing MCNs from IPMNs.
- name: Adenoma-Carcinoma Progression
description: >-
MCNs can progress through a stepwise sequence from benign cystadenoma with low-grade
dysplasia to borderline dysplasia, high-grade dysplasia (carcinoma in situ), and
ultimately invasive mucinous cystadenocarcinoma. This progression is driven by
accumulation of oncogene activation and tumor suppressor inactivation.
biological_processes:
- preferred_term: cell population proliferation
term:
id: GO:0008283
label: cell population proliferation
evidence:
- reference: PMID:10721805
reference_title: "Mucinous cystic neoplasms of the pancreas."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Partial resection should be avoided as evidence suggests that mucinous cystic
neoplasms can progress from adenomas to borderline lesions to carcinomas in situ
to invasive carcinomas over time; partial resection should be avoided if possible.
explanation: >-
Describes the stepwise progression model from adenoma through borderline and
in situ carcinoma to invasive carcinoma in mucinous cystic neoplasms.
- reference: PMID:28570009
reference_title: "Mucinous cystic neoplasms of the liver and pancreas: relationship between KRAS driver mutations and disease progression."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
KRAS mutations were uncommon in cases of low-grade dysplasia (1/20, 5%), whereas
KRAS was mutated in all cases of higher grades, except for one liver MCN with
intermediate-grade dysplasia (4/5, 80%; P = 0.002).
explanation: >-
Demonstrates that KRAS mutations are strongly associated with higher-grade
dysplasia in MCNs, supporting the role of KRAS as a driver in
adenoma-carcinoma progression.
- name: KRAS-Driven Oncogenesis via MAPK Cascade
description: >-
KRAS activating mutations are the primary initiating driver in pancreatic MCNs,
with frequency that is grade-dependent (50% in LG, 100% in HG/INV lesions).
Identical KRAS mutations present in
both low-grade and higher-grade areas of individual tumors indicate clonal
progression. KRAS mutations are also associated with increased mucin expression
(MUC1, MUC2, MUC5AC) and multilocular cystic appearance.
biological_processes:
- preferred_term: MAPK cascade
term:
id: GO:0000165
label: MAPK cascade
evidence:
- reference: PMID:28570009
reference_title: "Mucinous cystic neoplasms of the liver and pancreas: relationship between KRAS driver mutations and disease progression."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
KRAS mutations appear to be major driver genetic alterations in both liver and
pancreatic MCNs. As identical KRAS mutations were present in low-grade and
higher-grade areas in individual cases, KRAS mutations occurring in low-grade
MCNs may lead to tumour progression.
explanation: >-
Establishes KRAS as the primary oncogenic driver in pancreatic MCNs through
molecular analysis of 25 surgical cases, showing clonal progression from
low-grade to higher-grade dysplasia.
- reference: PMID:35066614
reference_title: "RNF43 as a predictor of malignant transformation of pancreatic mucinous cystic neoplasm."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
MCNs frequently harbored KRAS mutations, at rates of 100% in HG/INV lesions
and 50% in LG lesions of HG/INV and LG cases.
explanation: >-
Study of 106 MCN cases quantifies grade-dependent KRAS mutation rates,
establishing 50% in low-grade and 100% in high-grade/invasive lesions.
- reference: PMID:34099908
reference_title: "Early detection of pancreatic cancer using DNA-based molecular approaches."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We also discuss the most prevalent genetic alterations in these precancerous
lesions, including somatic mutations in the oncogenes KRAS and GNAS as well as
tumour suppressor genes CDKN2A, TP53 and SMAD4.
explanation: >-
Review confirms KRAS as one of the most prevalent genetic alterations in
pancreatic precancerous lesions including mucinous cystic neoplasms.
downstream:
- target: Mucinous Epithelial Proliferation
description: >-
KRAS activation drives epithelial proliferation and mucin expression
in MCN cells.
- target: Adenoma-Carcinoma Progression
description: >-
KRAS mutations are enriched in higher-grade dysplasia, driving
progression through the adenoma-carcinoma sequence.
- name: RNF43 Loss and Wnt Pathway Dysregulation
description: >-
RNF43 loss-of-function mutations are found in MCNs and are significantly
associated with malignant transformation. RNF43 normally acts as a negative
regulator of Wnt signaling by promoting degradation of Wnt receptors. Loss
of RNF43 leads to reduced protein expression and aberrant beta-catenin
nuclear localization, activating the Wnt pathway. In contrast to IPMNs, GNAS
mutations are rare or absent in MCNs.
biological_processes:
- preferred_term: Wnt signaling pathway
term:
id: GO:0016055
label: Wnt signaling pathway
evidence:
- reference: PMID:35066614
reference_title: "RNF43 as a predictor of malignant transformation of pancreatic mucinous cystic neoplasm."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The frequency of RNF43 mutations was significantly higher in HG/INV cases
than in LG cases. Furthermore, HG/INV lesions (56%) and LG lesions (33%) of
HG/INV cases possessed RNF43 mutation, whereas no such mutation was detected
in any LG cases.
explanation: >-
Study of 106 MCN cases directly demonstrates RNF43 mutations are enriched
in high-grade/invasive lesions, supporting RNF43 loss as a driver of Wnt
pathway dysregulation in MCN progression.
- reference: PMID:28570009
reference_title: "Mucinous cystic neoplasms of the liver and pancreas: relationship between KRAS driver mutations and disease progression."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
KRAS, GNAS, RNF43 and PIK3CA were sequenced in 25 surgical cases of
hepatopancreatic MCN. Molecular features were correlated with
clinicopathological and immunohistochemical findings. KRAS mutations were
identified in five cases (20%), whereas GNAS, RNF43 and PIK3CA were wild-type
in all cases.
explanation: >-
This smaller study of 25 cases did not find RNF43 mutations, likely due to
sample size and enrichment for low-grade lesions. Confirms GNAS is absent
in MCNs, distinguishing them from IPMNs.
downstream:
- target: Adenoma-Carcinoma Progression
description: >-
RNF43 loss activates Wnt signaling, promoting dysplastic progression
from low-grade to high-grade/invasive MCN.
- name: Tumor Suppressor Inactivation in Malignant Progression
description: >-
Progression from low-grade to high-grade dysplasia and invasive carcinoma is
associated with acquisition of tumor suppressor alterations including TP53,
SMAD4/DPC4, CDKN2A/p16, and TGFBR2. These alterations are often restricted
to invasive components, consistent with late events in malignant transformation.
The TGF-beta signaling pathway (SMAD4/TGFBR2) is particularly important in
MCN progression.
biological_processes:
- preferred_term: transforming growth factor beta receptor signaling pathway
term:
id: GO:0007179
label: transforming growth factor beta receptor signaling pathway
evidence:
- reference: PMID:34099908
reference_title: "Early detection of pancreatic cancer using DNA-based molecular approaches."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We also discuss the most prevalent genetic alterations in these precancerous
lesions, including somatic mutations in the oncogenes KRAS and GNAS as well as
tumour suppressor genes CDKN2A, TP53 and SMAD4.
explanation: >-
Identifies TP53, CDKN2A, and SMAD4 as key tumor suppressor genes altered in
pancreatic precancerous lesions including MCNs, supporting the progressive
accumulation of genetic alterations model.
downstream:
- target: Adenoma-Carcinoma Progression
description: >-
Inactivation of TP53, SMAD4, and CDKN2A drives late-stage progression
from high-grade dysplasia to invasive carcinoma.
phenotypes:
- name: Pancreatic Cysts
category: Gastrointestinal
frequency: OBLIGATE
notes: >-
MCNs present as mucin-filled cystic lesions, typically septated, in the body
or tail of the pancreas without communication with the pancreatic duct.
phenotype_term:
preferred_term: Pancreatic cysts
term:
id: HP:0001737
label: Pancreatic cysts
evidence:
- reference: PMID:20043327
reference_title: "Pancreatic cysts: preoperative diagnosis and clinical management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Mucinous cystic neoplasms typically arise in the body or tail of the pancreas
of middle-aged women and demonstrate a septated cyst without dilatation of the
main pancreatic duct.
explanation: >-
Describes the characteristic cystic presentation of MCNs as septated cysts
in the body or tail of the pancreas.
- name: Abdominal Pain
category: Gastrointestinal
frequency: FREQUENT
phenotype_term:
preferred_term: Abdominal pain
term:
id: HP:0002027
label: Abdominal pain
evidence:
- reference: PMID:21128317
reference_title: "Management of mucinous cystic neoplasms of the pancreas."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
The majority of MCNs are slow growing and asymptomatic.
explanation: >-
While most MCNs are asymptomatic, abdominal pain is the most common
presenting symptom when symptoms do occur, as noted across clinical series.
- name: Abdominal Mass
category: Gastrointestinal
frequency: OCCASIONAL
notes: >-
Large MCNs may present as a palpable abdominal mass. MCNs are typically
4-5 cm at diagnosis and located in the body or tail.
phenotype_term:
preferred_term: Abdominal mass
term:
id: HP:0031500
label: Abdominal mass
evidence:
- reference: PMID:28416122
reference_title: "Patients with a resected pancreatic mucinous cystic neoplasm have a better prognosis than patients with an intraductal papillary mucinous neoplasm: A large single institution series."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
MCNs presented almost exclusively in middle-aged women (median 47.5
years, 96.5% female) as solitary (100%), macrocystic (94.2%) lesions in the
distal pancreas (92.1%).
explanation: >-
Large single-institution series of 142 MCNs demonstrates that MCNs
are macrocystic (94.2%) and large (median 4.2 cm), consistent with
presentation as a palpable abdominal mass.
- name: Pancreatic Mass
category: Gastrointestinal
frequency: FREQUENT
phenotype_term:
preferred_term: Pancreatic mass
term:
id: HP:6000409
label: Pancreatic mass
evidence:
- reference: PMID:21128317
reference_title: "Management of mucinous cystic neoplasms of the pancreas."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
MCNs are pancreatic mucin-producing cysts with a distinctive ovarian-type stroma
localized in the body-tail of the gland and occurring in middle-aged females.
explanation: >-
MCNs present as discrete pancreatic masses localized in the body-tail of
the pancreas.
- name: Weight Loss
category: Constitutional
frequency: OCCASIONAL
notes: >-
Weight loss may occur as a nonspecific symptom in patients with large or
malignant MCNs, though most MCNs are asymptomatic.
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
evidence:
- reference: PMID:29574408
reference_title: "European evidence-based guidelines on pancreatic cystic neoplasms."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Resection is also recommended for MCN which are symptomatic or have risk
factors (ie, mural nodule) irrespective of their size
explanation: >-
European guidelines recognize symptomatic MCNs as indication for resection.
Weight loss is a known nonspecific symptom but is not named in this snippet.
- name: Nausea
category: Gastrointestinal
frequency: OCCASIONAL
notes: >-
Nausea is a nonspecific gastrointestinal symptom that may occur in
symptomatic MCN patients due to mass effect.
phenotype_term:
preferred_term: Nausea
term:
id: HP:0002018
label: Nausea
evidence:
- reference: PMID:29574408
reference_title: "European evidence-based guidelines on pancreatic cystic neoplasms."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Resection is also recommended for MCN which are symptomatic or have risk
factors (ie, mural nodule) irrespective of their size
explanation: >-
European guidelines recognize that MCNs can be symptomatic, supporting
nausea as a possible symptom, though nausea is not named specifically.
- name: Vomiting
category: Gastrointestinal
frequency: OCCASIONAL
notes: >-
Vomiting may accompany nausea in symptomatic MCN patients, particularly
with larger lesions causing mass effect on adjacent structures.
phenotype_term:
preferred_term: Vomiting
term:
id: HP:0002013
label: Vomiting
evidence:
- reference: PMID:29574408
reference_title: "European evidence-based guidelines on pancreatic cystic neoplasms."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Resection is also recommended for MCN which are symptomatic or have risk
factors (ie, mural nodule) irrespective of their size
explanation: >-
European guidelines recognize that MCNs can be symptomatic, indirectly
supporting vomiting as a possible symptom, though not named specifically.
- name: Back Pain
category: Musculoskeletal
frequency: OCCASIONAL
notes: >-
Back pain can occur when MCNs in the body or tail of the pancreas compress
or involve retroperitoneal structures.
phenotype_term:
preferred_term: Back pain
term:
id: HP:0003418
label: Back pain
evidence:
- reference: PMID:29574408
reference_title: "European evidence-based guidelines on pancreatic cystic neoplasms."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Resection is also recommended for MCN which are symptomatic or have risk
factors (ie, mural nodule) irrespective of their size
explanation: >-
European guidelines recognize symptomatic MCNs; back pain from
retroperitoneal body/tail lesions is a known symptom but not named here.
- name: New-Onset Diabetes Mellitus
category: Endocrine
frequency: OCCASIONAL
notes: >-
New-onset diabetes mellitus can occur due to pancreatic parenchymal
compression or destruction by the cystic neoplasm, and is considered a
relative indication for surgical resection.
phenotype_term:
preferred_term: Diabetes mellitus
term:
id: HP:0000819
label: Diabetes mellitus
evidence:
- reference: PMID:29574408
reference_title: "European evidence-based guidelines on pancreatic cystic neoplasms."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
MCN ≥40 mm should undergo surgical resection. Resection is also recommended
for MCN which are symptomatic or have risk factors (ie, mural nodule)
irrespective of their size
explanation: >-
The MCN-specific section of European guidelines references symptomatic MCNs
as an indication for resection without enumerating individual symptoms.
New-onset diabetes mellitus is a recognized symptom of pancreatic cystic
neoplasms but is not specifically named in the MCN management section.
- name: Pancreatitis
category: Gastrointestinal
frequency: OCCASIONAL
phenotype_term:
preferred_term: Pancreatitis
term:
id: HP:0001733
label: Pancreatitis
evidence:
- reference: PMID:29574408
reference_title: "European evidence-based guidelines on pancreatic cystic neoplasms."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
MCN ≥40 mm should undergo surgical resection. Resection is also recommended
for MCN which are symptomatic or have risk factors (ie, mural nodule)
irrespective of their size
explanation: >-
The MCN-specific section of European guidelines references symptomatic MCNs
as an indication for resection without enumerating individual symptoms.
Pancreatitis is a recognized symptom of pancreatic cystic neoplasms but is
not specifically named in the MCN management section.
- name: Jaundice
category: Gastrointestinal
frequency: VERY_RARE
notes: >-
Jaundice may occur with MCNs located in or compressing the pancreatic head,
but this is uncommon since most MCNs arise in the body or tail.
phenotype_term:
preferred_term: Jaundice
term:
id: HP:0000952
label: Jaundice
evidence:
- reference: PMID:29574408
reference_title: "European evidence-based guidelines on pancreatic cystic neoplasms."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
MCN ≥40 mm should undergo surgical resection. Resection is also recommended
for MCN which are symptomatic or have risk factors (ie, mural nodule)
irrespective of their size
explanation: >-
The MCN-specific section of European guidelines references symptomatic MCNs
as an indication for resection without enumerating individual symptoms.
Jaundice is a recognized symptom of pancreatic cystic neoplasms but is not
specifically named in the MCN management section.
has_subtypes:
- name: Mucinous Cystadenoma (Low-Grade Dysplasia)
description: >-
Benign MCN containing a single layer of mucin-producing columnar epithelium
lacking significant atypia. Completely resected lesions follow a benign course.
evidence:
- reference: PMID:10721805
reference_title: "Mucinous cystic neoplasms of the pancreas."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Mucinous cystadenomas contain a single layer of mucin-producing, columnar
epithelium lacking significant atypia.
explanation: >-
Defines mucinous cystadenoma as low-grade MCN with columnar epithelium
lacking atypia.
- name: Borderline Mucinous Cystic Neoplasm
description: >-
MCN containing cells with moderate atypia, representing an intermediate
stage in the adenoma-carcinoma sequence.
evidence:
- reference: PMID:10721805
reference_title: "Mucinous cystic neoplasms of the pancreas."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Borderline mucinous cystic neoplasms contain cells with moderate atypia.
explanation: Defines the borderline category of MCN.
- name: Mucinous Cystic Neoplasm with In Situ Carcinoma
description: >-
MCN showing significant architectural and cytological atypia, representing
high-grade dysplasia. Completely resected lesions follow benign courses.
evidence:
- reference: PMID:10721805
reference_title: "Mucinous cystic neoplasms of the pancreas."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Mucinous cystic neoplasms with in situ carcinoma show significant architectural
and cytological atypia.
explanation: Defines the in situ carcinoma subtype of MCN.
- name: Invasive Mucinous Cystadenocarcinoma
description: >-
MCN with invasive carcinoma, representing the end stage of the
adenoma-carcinoma progression sequence with significantly worse prognosis.
evidence:
- reference: PMID:10721805
reference_title: "Mucinous cystic neoplasms of the pancreas."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
When invasive carcinoma is present in association with a mucinous cystic
neoplasm, then the diagnosis of invasive mucinous cystadenocarcinoma should
be made.
explanation: >-
Defines the invasive carcinoma subtype of MCN as the most advanced stage.
genetic:
- name: KRAS Mutations
gene_term:
preferred_term: KRAS
term:
id: hgnc:6407
label: KRAS
presence: SOMATIC
association: PREDISPOSING
notes: >-
KRAS oncogene mutations are the primary driver genetic alterations in pancreatic
MCNs. Frequency is grade-dependent, with 50% in LG lesions and 100% in HG/INV
lesions in a large study of 106 cases. A smaller series of 25 cases found 20%
overall (5% LG, 80% higher-grade). KRAS mutations are associated with increased
mucin expression and multilocular appearance.
evidence:
- reference: PMID:28570009
reference_title: "Mucinous cystic neoplasms of the liver and pancreas: relationship between KRAS driver mutations and disease progression."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
KRAS mutations were identified in five cases (20%), whereas GNAS, RNF43 and
PIK3CA were wild-type in all cases. KRAS mutations were uncommon in cases of
low-grade dysplasia (1/20, 5%), whereas KRAS was mutated in all cases of higher
grades, except for one liver MCN with intermediate-grade dysplasia (4/5, 80%;
P = 0.002).
explanation: >-
Molecular analysis of 25 MCN cases establishing KRAS mutation rates across
different dysplasia grades.
- name: RNF43 Loss-of-Function
gene_term:
preferred_term: RNF43
term:
id: hgnc:18505
label: RNF43
presence: SOMATIC
association: PREDISPOSING
notes: >-
RNF43 inactivating mutations are found in MCNs and are significantly enriched
in high-grade and invasive lesions. RNF43 normally promotes degradation of
Wnt receptors, acting as a tumor suppressor. Loss of RNF43 leads to aberrant
beta-catenin expression and Wnt signaling activation.
evidence:
- reference: PMID:35066614
reference_title: "RNF43 as a predictor of malignant transformation of pancreatic mucinous cystic neoplasm."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
These results suggest that RNF43 mutations may be involved in and predictive
of malignant transformation from an early stage of MCN.
explanation: >-
Study of 106 MCN cases demonstrating RNF43 mutations in 56% of high-grade/
invasive lesions, with RNF43 loss correlating with aberrant Wnt signaling.
- name: TP53 Mutations in Progression
gene_term:
preferred_term: TP53
term:
id: hgnc:11998
label: TP53
presence: SOMATIC
association: PREDISPOSING
notes: >-
TP53 mutations are late events associated with progression to high-grade
dysplasia and invasive carcinoma in MCNs.
evidence:
- reference: PMID:34099908
reference_title: "Early detection of pancreatic cancer using DNA-based molecular approaches."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We also discuss the most prevalent genetic alterations in these precancerous
lesions, including somatic mutations in the oncogenes KRAS and GNAS as well as
tumour suppressor genes CDKN2A, TP53 and SMAD4.
explanation: >-
Identifies TP53 as one of the key tumor suppressor genes altered during
malignant progression of pancreatic precancerous lesions.
- name: SMAD4 Loss in Malignant Progression
gene_term:
preferred_term: SMAD4
term:
id: hgnc:6770
label: SMAD4
presence: SOMATIC
association: PREDISPOSING
notes: >-
SMAD4/DPC4 loss is associated with invasive progression of MCNs via disruption
of TGF-beta signaling. Often restricted to invasive components.
evidence:
- reference: PMID:34099908
reference_title: "Early detection of pancreatic cancer using DNA-based molecular approaches."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We also discuss the most prevalent genetic alterations in these precancerous
lesions, including somatic mutations in the oncogenes KRAS and GNAS as well as
tumour suppressor genes CDKN2A, TP53 and SMAD4.
explanation: >-
Identifies SMAD4 as a key tumor suppressor gene altered in pancreatic
precancerous lesion progression including MCNs.
- name: CDKN2A Inactivation
gene_term:
preferred_term: CDKN2A
term:
id: hgnc:1787
label: CDKN2A
presence: SOMATIC
association: PREDISPOSING
notes: >-
CDKN2A/p16 inactivation is associated with progression to higher-grade
dysplasia and invasive carcinoma in MCNs.
evidence:
- reference: PMID:34099908
reference_title: "Early detection of pancreatic cancer using DNA-based molecular approaches."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We also discuss the most prevalent genetic alterations in these precancerous
lesions, including somatic mutations in the oncogenes KRAS and GNAS as well as
tumour suppressor genes CDKN2A, TP53 and SMAD4.
explanation: >-
Identifies CDKN2A as a key tumor suppressor gene altered during malignant
progression of pancreatic precancerous lesions.
treatments:
- name: Surgical Resection
description: >-
Surgical resection (typically distal pancreatectomy) is the standard treatment
for MCNs >=40 mm or those with risk features (mural nodule) or symptoms,
per 2018 European guidelines. Complete resection is curative for non-invasive
MCNs. Partial resection should be avoided due to the risk of adenoma-carcinoma
progression. MCNs <40 mm without risk features may be safely surveilled.
treatment_term:
preferred_term: surgical resection
term:
id: MAXO:0000448
label: surgical resection
evidence:
- reference: PMID:10721805
reference_title: "Mucinous cystic neoplasms of the pancreas."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Completely removed mucinous cystadenomas, borderline mucinous cystic neoplasms,
and mucinous cystic neoplasms with in situ carcinoma follow benign courses.
Partial resection should be avoided as evidence suggests that mucinous cystic
neoplasms can progress from adenomas to borderline lesions to carcinomas in situ
to invasive carcinomas over time; partial resection should be avoided if possible.
explanation: >-
Demonstrates that complete resection is curative for non-invasive MCNs and
that partial resection risks leaving tissue that may progress to carcinoma.
- reference: PMID:29574408
reference_title: "European evidence-based guidelines on pancreatic cystic neoplasms."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
MCN ≥40 mm should undergo surgical resection. Resection is also recommended
for MCN which are symptomatic or have risk factors (ie, mural nodule)
irrespective of their size
explanation: >-
2018 European evidence-based guidelines specify size-based criteria for
surgical resection of MCNs, superseding earlier recommendations for
universal resection.
- reference: PMID:21128317
reference_title: "Management of mucinous cystic neoplasms of the pancreas."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Surgery is indicated for all MCNs.
explanation: >-
2010 systematic review recommended surgery for all MCNs; this has been
superseded by 2018 European guidelines allowing surveillance for MCNs
<40 mm without risk features.
- name: Surveillance for Malignancy
description: >-
Postoperative surveillance is recommended after resection of MCNs, particularly
for those with higher-grade dysplasia or invasive components, to monitor for
recurrence. For unresected MCNs <40mm without risk features, surveillance with
MRI every 6 months for the first year then annually is recommended.
treatment_term:
preferred_term: surveillance for malignancies
term:
id: MAXO:0001492
label: surveillance for malignancies
evidence:
- reference: PMID:29574408
reference_title: "European evidence-based guidelines on pancreatic cystic neoplasms."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
MCN measuring <40 mm without a mural nodule or symptoms may undergo
surveillance with MRI, EUS, or a combination of both.
explanation: >-
European evidence-based guidelines recommend surveillance with MRI and/or
EUS for MCNs <40mm without concerning features.
- reference: PMID:29574408
reference_title: "European evidence-based guidelines on pancreatic cystic neoplasms."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Surveillance is recommended every 6 months for the first year, then annually
if no changes are observed. Patients with an MCN measuring <40 mm and with no
concerning features or symptoms should have lifelong surveillance as long as
they are fit for surgery
explanation: >-
Specifies the surveillance interval and duration for small asymptomatic MCNs.
datasets:
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on the pathophysiology of Pancreatic Mucinous Cystadenoma. Focus on the molecular and cellular mechanisms underlying disease progression.
Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs
Nomenclature. “Pancreatic mucinous cystadenoma” is most commonly discussed in contemporary pathology and clinical guidelines as pancreatic mucinous cystic neoplasm (MCN), a mucin-producing cystic epithelial neoplasm. A defining criterion is that MCNs do not communicate with the pancreatic ductal system and are histologically defined by a characteristic ovarian-type subepithelial stroma. (mormul2023rarenonneuroendocrinepancreatic pages 6-8, hu2024molecularpathologyof pages 2-4)
Epidemiology and anatomy. MCNs occur predominantly in women (reported >98% female in a 2024 review) and typically arise in the pancreatic body/tail, supporting a long-standing concept of a hormonally responsive stromal niche. (hu2024molecularpathologyof pages 2-4, mormul2023rarenonneuroendocrinepancreatic pages 6-8)
Diagnostic hallmarks relevant to pathophysiology. Because MCNs lack duct communication, cyst fluid typically shows low amylase (<250 U/L), consistent with a closed cyst compartment rather than ductal mixing. (mormul2023rarenonneuroendocrinepancreatic pages 8-9)
MONDO ID. Not identified from the retrieved evidence in this run.
Across recent reviews, the core mechanistic model for MCN progression is oncogenic RAS/MAPK signaling activation (usually via KRAS) followed by acquisition of alterations in tumor suppressor pathways that permit high-grade dysplasia and invasion.
A more explicitly “progression-ordered” view from a genomic review (2025) also states that SMAD4 expression is preserved in low/high-grade dysplasia but lost in a high proportion of invasive MCN carcinomas, with TP53/CDKN2A being later alterations, consistent with a multistep tumor suppressor erosion model. (yang2025genomicalterationsin pages 4-6)
A distinctive and mechanistically important feature of MCN is the presence of ovarian-type stroma that is not merely diagnostic but biologically active.
Interpretation (expert synthesis). Collectively, these data support the hypothesis that MCN progression occurs in an epithelial–stromal unit where (i) epithelial KRAS-driven mucinous neoplasia and (ii) a hormone-responsive, steroidogenic stromal compartment may provide permissive growth cues (paracrine signaling, local hormone production, stromal remodeling), thereby shaping the trajectory toward dysplasia and invasion. (ishida2016immunohistochemicalanalysisof pages 2-4, fukushima2014mucinouscysticneoplasms pages 5-7)
TGF-β signaling via SMAD4 is repeatedly implicated as a suppressive barrier whose attenuation is associated with progression.
Important nuance. The same evidence also notes that these murine cysts do not possess ovarian-like stroma and stromal cells do not express PR or ER, implying that the KRAS–SMAD4 axis can generate an MCN-like epithelial phenotype independent of the human hallmark ovarian-type stroma, and that additional (species- or context-specific) determinants likely drive formation of the ovarian-type stromal compartment in humans. (izeradjene2007kras(g12d)andsmad4dpc4 pages 2-5)
Stromal modulation of Wnt signaling is implicated in MCN biology.
Key genes supported by retrieved evidence include: * KRAS (early driver; RAS/MAPK). (hu2024molecularpathologyof pages 2-4, fukushima2014mucinouscysticneoplasms pages 5-7) * RNF43 (Wnt regulation; implicated in mucinous cyst tumorigenesis). (hu2024molecularpathologyof pages 2-4) * TP53, CDKN2A, SMAD4 (late/advanced lesions and invasion; TGF-β suppression and cell-cycle checkpoints). (fukushima2014mucinouscysticneoplasms pages 5-7, yang2025genomicalterationsin pages 4-6) * ESR1/ER, PGR/PR, NR5A1/SF-1, steroidogenic enzymes (CYP11A1/P450scc, CYP17A1/P450c17, HSD3B/3β-HSD) in ovarian-type stroma. (ishida2016immunohistochemicalanalysisof pages 2-4, fukushima2014mucinouscysticneoplasms pages 7-8)
| Category | Gene/Protein (HGNC symbol) | Pathway/Process | Evidence summary (1 sentence) | Key citation IDs |
|---|---|---|---|---|
| Early driver | KRAS | RAS–MAPK signaling | Activating mutations occur in roughly 50–66% of MCNs as early events driving neoplasia. | (hu2024molecularpathologyof pages 2-4, fukushima2014mucinouscysticneoplasms pages 5-7) |
| Early driver | RNF43 | Wnt signaling (E3 ligase negative regulator) | Loss-of-function alterations are reported in MCNs, implicating dysregulated Wnt signaling in early tumorigenesis. | (hu2024molecularpathologyof pages 2-4) |
| Late/advanced | TP53 | DNA damage response/tumor suppression | Alterations are enriched in high-grade dysplasia and invasive components of MCNs. | (hu2024molecularpathologyof pages 2-4, fukushima2014mucinouscysticneoplasms pages 5-7) |
| Late/advanced | SMAD4 | TGF-β signaling | Retained in noninvasive MCN but lost in a high proportion of invasive cases; cooperates with KRAS to promote progression. | (yang2025genomicalterationsin pages 4-6, izeradjene2007kras(g12d)andsmad4dpc4 pages 2-5) |
| Late/advanced | CDKN2A (p16) | Cell-cycle checkpoint | Inactivation is associated with advanced/invasive lesions in MCN. | (hu2024molecularpathologyof pages 2-4, fukushima2014mucinouscysticneoplasms pages 5-7) |
| Late/advanced | PIK3CA | PI3K–AKT–mTOR signaling | Mutations are among genes linked to advanced neoplasia in mucinous pancreatic cysts. | (hu2024molecularpathologyof pages 2-4) |
| Late/advanced | EGFR | RTK signaling | Overexpressed in ~61% of MCNs with invasive components, suggesting growth-factor pathway activation. | (fukushima2014mucinouscysticneoplasms pages 5-7) |
| Stromal biology | ESR1/ESR2 (ERα/ERβ) | Estrogen receptor signaling | Ovarian-type stroma shows strong nuclear ER immunoreactivity (high H-scores), indicating hormone responsiveness. | (ishida2016immunohistochemicalanalysisof pages 2-4, fukushima2014mucinouscysticneoplasms pages 5-7) |
| Stromal biology | PGR (PR) | Progesterone receptor signaling | PR expression is robust in ovarian-type stroma, consistent with a hormonally responsive microenvironment. | (ishida2016immunohistochemicalanalysisof pages 2-4) |
| Stromal biology | AR | Androgen receptor signaling | AR nuclear expression is detected in ovarian-type stroma as part of a steroid hormone receptor program. | (ishida2016immunohistochemicalanalysisof pages 4-5) |
| Stromal biology | NR5A1 (SF-1) | Steroidogenesis transcriptional control | SF-1 is highly expressed in ovarian-type stroma (H-score ~112), driving steroidogenic enzyme transcription. | (ishida2016immunohistochemicalanalysisof pages 2-4) |
| Stromal biology | CYP11A1 / CYP17A1 / HSD3B1/2 | Steroid biosynthesis enzymes | Steroidogenic enzymes are expressed in ovarian-type stroma (P450scc 45%, P450c17 75%, 3β-HSD 65%). | (ishida2016immunohistochemicalanalysisof pages 1-2, ishida2016immunohistochemicalanalysisof pages 4-5) |
| Stromal biology | SFRP1 | Wnt pathway modulation | Secreted frizzled-related protein is overexpressed in stroma, implicating Wnt modulation in MCN development. | (fukushima2014mucinouscysticneoplasms pages 7-8) |
| Stromal biology | CTNNB1 (β-catenin) | Wnt/β-catenin signaling | Nuclear β-catenin is observed in ovarian-like stroma in a subset, consistent with Wnt activation. | (fukumura2022intralobulardistributionof pages 7-8) |
Table: Summary of key molecular players and dysregulated pathways in pancreatic mucinous cystic neoplasm (MCN), organized by early drivers, late/advanced alterations, and stromal biology. Citations point to recent reviews and primary studies supporting each entry.
Mechanistically supported processes include: * RAS protein signal transduction / MAPK cascade activation (KRAS). (hu2024molecularpathologyof pages 2-4) * Wnt signaling pathway dysregulation (RNF43 loss; stromal sFRP modulation; β-catenin nuclear localization). (hu2024molecularpathologyof pages 2-4, fukushima2014mucinouscysticneoplasms pages 7-8, fukumura2022intralobulardistributionof pages 7-8) * TGF-β signaling attenuation (SMAD4 loss in invasion; KRAS–SMAD4 cooperation in experimental models). (izeradjene2007kras(g12d)andsmad4dpc4 pages 2-5, yang2025genomicalterationsin pages 4-6) * Steroid biosynthesis and hormone receptor signaling (ovarian-type stroma SF-1 and steroidogenic enzymes). (ishida2016immunohistochemicalanalysisof pages 2-4, fukushima2014mucinouscysticneoplasms pages 7-8)
Key cellular locations implied by the evidence: * Nucleus: ER/PR/SF-1 (transcriptional regulators) and tumor suppressors (TP53, SMAD4) exert nuclear functions. (ishida2016immunohistochemicalanalysisof pages 2-4, fukushima2014mucinouscysticneoplasms pages 5-7) * Cytoplasm/ER–mitochondrial interfaces: steroidogenic enzymes and STAR-mediated cholesterol transport underpin steroidogenesis in stromal cells. (fukushima2014mucinouscysticneoplasms pages 5-7, fukushima2014mucinouscysticneoplasms pages 7-8) * Extracellular space: secreted modulators (e.g., sFRP) affecting Wnt signaling act in the stromal compartment. (fukushima2014mucinouscysticneoplasms pages 7-8)
A knowledge-base-ready staging model supported by the retrieved evidence is: 1. Initiation: KRAS activation ± RNF43 alteration in mucinous epithelium; establishment of ovarian-type stroma with hormone receptor program and steroidogenic capacity. (hu2024molecularpathologyof pages 2-4, ishida2016immunohistochemicalanalysisof pages 2-4) 2. Progression: cyst enlargement/complexity and acquisition of additional genetic hits; RNF43 deficiency may potentiate KRAS hyperactivity per 2023 review. (mormul2023rarenonneuroendocrinepancreatic pages 8-9) 3. High-grade dysplasia: enrichment of TP53/CDKN2A alterations; imaging correlates (wall thickening, nodules). (fukushima2014mucinouscysticneoplasms pages 5-7, mormul2023rarenonneuroendocrinepancreatic pages 6-8) 4. Invasive carcinoma: SMAD4 loss becomes common; EGFR overexpression reported in invasive-associated MCN; invasive transformation modeled experimentally with KRAS+SMAD4 disruption. (fukushima2014mucinouscysticneoplasms pages 5-7, izeradjene2007kras(g12d)andsmad4dpc4 pages 2-5, yang2025genomicalterationsin pages 4-6)
| Stage | Key histology/phenotype | Common molecular events | Stromal/microenvironment features | Clinical/imaging correlates | Key citation IDs |
|---|---|---|---|---|---|
| Initiation / low-grade | Unilocular/multilocular mucinous cyst, ovarian-type stroma, no duct communication; body/tail; predominantly female | Early KRAS activation (~50–66%); RNF43 alterations reported; GNAS uncommon in MCN | Ovarian-type stroma ER/PR/SF-1 positive; steroidogenic enzymes expressed (P450scc 45%, P450c17 75%, 3β-HSD 65%); Wnt modulation (sFRP overexpression) and nuclear β-catenin in subset | Low cyst-fluid amylase (<250 U/L); CEA >192–200 ng/mL supports mucinous (~80% accuracy); intracystic glucose ≤50 mg/dL (sens 92%, spec 87%) for mucinous; often incidental in perimenopausal women | (mormul2023rarenonneuroendocrinepancreatic pages 6-8, hu2024molecularpathologyof pages 2-4, ishida2016immunohistochemicalanalysisof pages 1-2, ishida2016immunohistochemicalanalysisof pages 2-4, fukushima2014mucinouscysticneoplasms pages 7-8, fukumura2022intralobulardistributionof pages 7-8, mormul2023rarenonneuroendocrinepancreatic pages 8-9, rogowska2024diagnosticsandmanagement pages 9-10) |
| Intermediate (progression) | Cyst growth/complexity (septa), emerging small mural nodules; increased epithelial proliferation | Clonal expansion of KRAS; RNF43 loss may potentiate KRAS and predict malignant transformation; emerging TP53/CDKN2A events | Persistently hormone-responsive ovarian-type stroma; activated Wnt signaling in stroma contributes to development | Size >3–4 cm and new septa/mural nodules increase concern; pancreatitis in ~9%; consider resection when ≥40 mm or with risk features | (mormul2023rarenonneuroendocrinepancreatic pages 8-9, fukushima2014mucinouscysticneoplasms pages 7-8, kloth2023diagnosticstructuredclassification pages 1-2, rogowska2024diagnosticsandmanagement pages 9-10) |
| High-grade dysplasia (CIS) | Marked epithelial atypia; prominent mural nodules (≥9 mm), thick/irregular walls (≥5 mm), enhancing septa | Acquisition of TP53 and CDKN2A alterations; SMAD4 typically retained in noninvasive HGD | Beginning desmoplasia around nodules; hormone receptor–positive stroma persists | CT detection of mural nodules strongly predicts malignancy (sens ~100%, spec ~98%); MRI T2 heterogeneity and wall thickening concerning | (hu2024molecularpathologyof pages 2-4, fukushima2014mucinouscysticneoplasms pages 5-7, yang2025genomicalterationsin pages 4-6, mormul2023rarenonneuroendocrinepancreatic pages 6-8, mormul2023rarenonneuroendocrinepancreatic pages 8-9) |
| Invasive carcinoma arising in MCN | Invasion beyond cyst wall with PDAC-like component | Frequent SMAD4 loss in invasive component; TP53/CDKN2A alterations; EGFR overexpression (~61% in invasive MCN) | Desmoplastic tumor microenvironment; ovarian-type stroma characteristic of background MCN | Solid/enhancing components; surgical resection indicated (e.g., ≥40 mm, nodules/solid parts, concerning EUS-FNA); KRAS+Smad4 cooperation yields invasive MCN in mouse models | (yang2025genomicalterationsin pages 4-6, fukushima2014mucinouscysticneoplasms pages 5-7, izeradjene2007kras(g12d)andsmad4dpc4 pages 2-5, kloth2023diagnosticstructuredclassification pages 1-2, rogowska2024diagnosticsandmanagement pages 9-10) |
Table: Stage-wise summary of pancreatic mucinous cystic neoplasm (MCN) progression linking histology, key molecular alterations, stromal biology, and clinical/imaging biomarkers. This table aids GO/CC annotation and clinical translation by mapping mechanisms to observable features with citations.
Clinical phenotypes and their mechanistic links: * Pancreatic cyst: direct result of mucinous epithelial proliferation and cyst formation. (mormul2023rarenonneuroendocrinepancreatic pages 6-8) * Pancreatitis: occurs in ~9% and may relate to local obstruction/inflammation from the cyst mass effect. (mormul2023rarenonneuroendocrinepancreatic pages 8-9) * Abdominal pain and incidental detection: clinical presentation guiding imaging and EUS evaluation within guideline pathways. (pitman2012revisedinternationalconsensus pages 1-2, mormul2023rarenonneuroendocrinepancreatic pages 8-9)
Recent summaries emphasize MRI/CT + EUS for characterization and malignant-risk assessment.
Risk of invasion / malignant transformation. A 2023 review reports invasive carcinoma in ~4.4–16.6% of MCNs. (mormul2023rarenonneuroendocrinepancreatic pages 6-8)
Low-risk subgroup. The same 2023 review reports that MCNs ≤3 cm without suspicious features have <0.4% invasive disease, supporting de-escalation strategies in carefully selected patients where appropriate. (mormul2023rarenonneuroendocrinepancreatic pages 8-9)
Diagnostic error. Misdiagnosis is a practical limitation; a 2023 review reports ~20% initial misdiagnosis rate for MCNs. (mormul2023rarenonneuroendocrinepancreatic pages 8-9)
Biomarker performance examples (2023–2024 sources). * CEA cutoff ~192–200 ng/mL: ~80% accuracy for mucinous cysts. (mormul2023rarenonneuroendocrinepancreatic pages 8-9) * Glucose ≤50 mg/dL: sensitivity 92%, specificity 87%, accuracy 90% for mucinous lesions. (rogowska2024diagnosticsandmanagement pages 9-10) * Kynurenine: ~90% sensitivity and 100% specificity reported in a cited metabolomic study summarized in a 2023 review. (mormul2023rarenonneuroendocrinepancreatic pages 8-9)
| Entity Type | Suggested Term/Label | Identifier | Rationale/relevance | Supporting citation IDs |
|---|---|---|---|---|
| Gene/Protein | KRAS | HGNC:6407 | Early activating driver mutation in ~50-66% of MCNs. | (hu2024molecularpathologyof pages 2-4, fukushima2014mucinouscysticneoplasms pages 5-7) |
| Gene/Protein | RNF43 | HGNC:18312 | Loss-of-function drives Wnt dysregulation in early tumorigenesis. | (hu2024molecularpathologyof pages 2-4, mormul2023rarenonneuroendocrinepancreatic pages 6-8) |
| Gene/Protein | TP53 | HGNC:11998 | Late alteration associated with high-grade dysplasia and invasion. | (hu2024molecularpathologyof pages 2-4, fukushima2014mucinouscysticneoplasms pages 5-7) |
| Gene/Protein | SMAD4 | HGNC:6770 | Loss typically indicates invasive carcinoma; cooperates with KRAS. | (izeradjene2007kras(g12d)andsmad4dpc4 pages 2-5, yang2025genomicalterationsin pages 4-6) |
| Gene/Protein | CDKN2A | HGNC:1787 | Inactivation (p16 loss) linked to malignant progression. | (hu2024molecularpathologyof pages 2-4, fukushima2014mucinouscysticneoplasms pages 5-7) |
| Gene/Protein | ESR1 (Estrogen Receptor 1) | HGNC:3467 | Strongly expressed in ovarian-type stroma; diagnostic hallmark. | (ishida2016immunohistochemicalanalysisof pages 2-4, fukushima2014mucinouscysticneoplasms pages 5-7) |
| Gene/Protein | PGR (Progesterone Receptor) | HGNC:8910 | Nuclear expression defines the characteristic ovarian-type stroma. | (ishida2016immunohistochemicalanalysisof pages 2-4) |
| Gene/Protein | NR5A1 (SF-1) | HGNC:7983 | Master regulator of steroidogenesis expressed in MCN stroma. | (ishida2016immunohistochemicalanalysisof pages 2-4, ishida2016immunohistochemicalanalysisof pages 4-5) |
| GO Biological Process | Steroid biosynthetic process | GO:0006694 | Ovarian-type stroma expresses enzymes (e.g., 3β-HSD) for local steroid production. | (ishida2016immunohistochemicalanalysisof pages 4-5, fukushima2014mucinouscysticneoplasms pages 7-8) |
| GO Biological Process | Wnt signaling pathway | GO:0016055 | RNF43 loss and stromal sFRP expression modulate Wnt activity in pathogenesis. | (hu2024molecularpathologyof pages 2-4, fukushima2014mucinouscysticneoplasms pages 7-8) |
| GO Biological Process | RAS protein signal transduction | GO:0007265 | KRAS activation is the primary initiating oncogenic event. | (hu2024molecularpathologyof pages 2-4) |
| GO Cellular Component | Nucleus | GO:0005634 | Location of key transcription factors (ER, PR, SF-1, p53, SMAD4). | (ishida2016immunohistochemicalanalysisof pages 2-4, fukushima2014mucinouscysticneoplasms pages 5-7) |
| HP Phenotype | Pancreatic cyst | HP:0001737 | The primary clinical manifestation is a mucin-filled cystic lesion. | (mormul2023rarenonneuroendocrinepancreatic pages 8-9, mormul2023rarenonneuroendocrinepancreatic pages 6-8) |
| HP Phenotype | Abdominal pain | HP:0002027 | Common symptom leading to diagnosis, or incidental finding. | (pitman2012revisedinternationalconsensus pages 1-2, mormul2023rarenonneuroendocrinepancreatic pages 8-9) |
| HP Phenotype | Pancreatitis | HP:0001733 | Occurs in ~9% of patients; inflammation associated with the cyst. | (mormul2023rarenonneuroendocrinepancreatic pages 8-9) |
| CL Cell Type | Pancreatic ductal cell | CL:0002079 | Epithelial lineage of the neoplastic cyst lining (mucin-producing). | (hu2024molecularpathologyof pages 2-4, mormul2023rarenonneuroendocrinepancreatic pages 6-8) |
| CL Cell Type | Stromal cell of ovary | CL:0000494 | MCN is defined by stroma mimicking ovarian stroma (theca-like cells). | (mormul2023rarenonneuroendocrinepancreatic pages 6-8, fukumura2022intralobulardistributionof pages 7-8) |
| UBERON Anatomy | Body of pancreas | UBERON:0001156 | Most common anatomical location for MCNs (body/tail region). | (mormul2023rarenonneuroendocrinepancreatic pages 8-9, yang2025genomicalterationsin pages 4-6) |
| UBERON Anatomy | Tail of pancreas | UBERON:0001157 | Frequent site of lesion; distal pancreatectomy is common treatment. | (mormul2023rarenonneuroendocrinepancreatic pages 8-9, pitman2012revisedinternationalconsensus pages 1-2) |
| ChEBI Chemical | Glucose | CHEBI:17234 | Low intracystic levels (<=50 mg/dL) distinguish mucinous from serous cysts. | (rogowska2024diagnosticsandmanagement pages 9-10, mormul2023rarenonneuroendocrinepancreatic pages 8-9) |
| ChEBI Chemical | Carcinoembryonic antigen (CEA) | CHEBI:192803 | Elevated cyst fluid levels (>192 ng/mL) suggest mucinous etiology. | (mormul2023rarenonneuroendocrinepancreatic pages 8-9, rogowska2024diagnosticsandmanagement pages 9-10) |
| ChEBI Chemical | Estradiol | CHEBI:16469 | Potential product of local steroidogenesis in ovarian-type stroma. | (ishida2016immunohistochemicalanalysisof pages 4-5) |
| ChEBI Chemical | Kynurenine | CHEBI:16668 | Metabolomic marker reported to be lower in MCNs. | (mormul2023rarenonneuroendocrinepancreatic pages 8-9) |
Table: A structured mapping of key genes, processes, phenotypes, and chemical entities associated with Pancreatic MCN to standard ontologies (HGNC, GO, HP, CL, UBERON, ChEBI) to support knowledge base integration.
References
(mormul2023rarenonneuroendocrinepancreatic pages 6-8): Agata Mormul, Emilia Włoszek, Julia Nowoszewska, Marta Fudalej, Michał Budzik, Anna Badowska-Kozakiewicz, and Andrzej Deptała. Rare non-neuroendocrine pancreatic tumours. Cancers, 15:2216, Apr 2023. URL: https://doi.org/10.3390/cancers15082216, doi:10.3390/cancers15082216. This article has 5 citations.
(hu2024molecularpathologyof pages 2-4): Yan Hu, Dan Jones, Ashwini K. Esnakula, Somashekar G. Krishna, and Wei Chen. Molecular pathology of pancreatic cystic lesions with a focus on malignant progression. Cancers, 16:1183, Mar 2024. URL: https://doi.org/10.3390/cancers16061183, doi:10.3390/cancers16061183. This article has 12 citations.
(mormul2023rarenonneuroendocrinepancreatic pages 8-9): Agata Mormul, Emilia Włoszek, Julia Nowoszewska, Marta Fudalej, Michał Budzik, Anna Badowska-Kozakiewicz, and Andrzej Deptała. Rare non-neuroendocrine pancreatic tumours. Cancers, 15:2216, Apr 2023. URL: https://doi.org/10.3390/cancers15082216, doi:10.3390/cancers15082216. This article has 5 citations.
(fukushima2014mucinouscysticneoplasms pages 5-7): Noriyoshi Fukushima and Giuseppe Zamboni. Mucinous cystic neoplasms of the pancreas: update on the surgical pathology and molecular genetics. Seminars in diagnostic pathology, 31 6:467-474, Nov 2014. URL: https://doi.org/10.1053/j.semdp.2014.08.007, doi:10.1053/j.semdp.2014.08.007. This article has 43 citations and is from a peer-reviewed journal.
(yang2025genomicalterationsin pages 4-6): Sen Yang, Tianqi Chen, Ming Cui, and Ya Hu. Genomic alterations in pancreatic cystic neoplasms: from molecular characterization to precision clinical management-conventional review. International journal of surgery, Jun 2025. URL: https://doi.org/10.1097/js9.0000000000002814, doi:10.1097/js9.0000000000002814. This article has 1 citations and is from a highest quality peer-reviewed journal.
(ishida2016immunohistochemicalanalysisof pages 1-2): Kazuyuki Ishida, Hironobu Sasano, Takuya Moriya, Yayoi Takahashi, Ryo Sugimoto, Yoshiharu Mue, Keigo Murakami, Fumiyoshi Fujishima, Yasuhiro Nakamura, Takanori Morikawa, Fuyuhiko Motoi, Takashi Suzuki, Michiaki Unno, and Tamotsu Sugai. Immunohistochemical analysis of steroidogenic enzymes in ovarian‐type stroma of pancreatic mucinous cystic neoplasms: comparative study of subepithelial stromal cells in intraductal papillary mucinous neoplasms of the pancreas. Pathology International, 66:281-287, May 2016. URL: https://doi.org/10.1111/pin.12406, doi:10.1111/pin.12406. This article has 17 citations and is from a peer-reviewed journal.
(ishida2016immunohistochemicalanalysisof pages 2-4): Kazuyuki Ishida, Hironobu Sasano, Takuya Moriya, Yayoi Takahashi, Ryo Sugimoto, Yoshiharu Mue, Keigo Murakami, Fumiyoshi Fujishima, Yasuhiro Nakamura, Takanori Morikawa, Fuyuhiko Motoi, Takashi Suzuki, Michiaki Unno, and Tamotsu Sugai. Immunohistochemical analysis of steroidogenic enzymes in ovarian‐type stroma of pancreatic mucinous cystic neoplasms: comparative study of subepithelial stromal cells in intraductal papillary mucinous neoplasms of the pancreas. Pathology International, 66:281-287, May 2016. URL: https://doi.org/10.1111/pin.12406, doi:10.1111/pin.12406. This article has 17 citations and is from a peer-reviewed journal.
(fukushima2014mucinouscysticneoplasms pages 7-8): Noriyoshi Fukushima and Giuseppe Zamboni. Mucinous cystic neoplasms of the pancreas: update on the surgical pathology and molecular genetics. Seminars in diagnostic pathology, 31 6:467-474, Nov 2014. URL: https://doi.org/10.1053/j.semdp.2014.08.007, doi:10.1053/j.semdp.2014.08.007. This article has 43 citations and is from a peer-reviewed journal.
(izeradjene2007kras(g12d)andsmad4dpc4 pages 2-5): Kamel Izeradjene, Chelsea Combs, Melissa Best, Aarthi Gopinathan, Amary Wagner, William M. Grady, Chu-Xia Deng, Ralph H. Hruban, N. Volkan Adsay, David A. Tuveson, and Sunil R. Hingorani. Kras(g12d) and smad4/dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer cell, 11 3:229-43, Mar 2007. URL: https://doi.org/10.1016/j.ccr.2007.01.017, doi:10.1016/j.ccr.2007.01.017. This article has 459 citations and is from a highest quality peer-reviewed journal.
(fukumura2022intralobulardistributionof pages 7-8): Yuki Fukumura, Yuko Kinowaki, Yoko Matsuda, Masaru Takase, Momoko Tonosaki, Masaaki Minagawa, Akio Saiura, Minoru Tanabe, Keiichi Okano, Yasuyuki Suzuki, Kota Kato, and Takashi Yao. Intralobular distribution of ovarian-like stroma in pancreatic mucinous cystic neoplasms: a discussion on its tumorigenesis. Scientific Reports, Feb 2022. URL: https://doi.org/10.1038/s41598-022-07416-9, doi:10.1038/s41598-022-07416-9. This article has 4 citations and is from a peer-reviewed journal.
(ishida2016immunohistochemicalanalysisof pages 4-5): Kazuyuki Ishida, Hironobu Sasano, Takuya Moriya, Yayoi Takahashi, Ryo Sugimoto, Yoshiharu Mue, Keigo Murakami, Fumiyoshi Fujishima, Yasuhiro Nakamura, Takanori Morikawa, Fuyuhiko Motoi, Takashi Suzuki, Michiaki Unno, and Tamotsu Sugai. Immunohistochemical analysis of steroidogenic enzymes in ovarian‐type stroma of pancreatic mucinous cystic neoplasms: comparative study of subepithelial stromal cells in intraductal papillary mucinous neoplasms of the pancreas. Pathology International, 66:281-287, May 2016. URL: https://doi.org/10.1111/pin.12406, doi:10.1111/pin.12406. This article has 17 citations and is from a peer-reviewed journal.
(rogowska2024diagnosticsandmanagement pages 9-10): Jagoda Rogowska, Jan Semeradt, Łukasz Durko, and Ewa Małecka-Wojciesko. Diagnostics and management of pancreatic cystic lesions—new techniques and guidelines. Journal of Clinical Medicine, 13:4644, Aug 2024. URL: https://doi.org/10.3390/jcm13164644, doi:10.3390/jcm13164644. This article has 20 citations.
(kloth2023diagnosticstructuredclassification pages 1-2): Christopher Kloth, Benedikt Haggenmüller, Annika Beck, Martin Wagner, Marko Kornmann, Jochen P. Steinacker, Nora Steinacker-Stanescu, Daniel Vogele, Meinrad Beer, Markus S. Juchems, and Stefan A. Schmidt. Diagnostic, structured classification and therapeutic approach in cystic pancreatic lesions: systematic findings with regard to the european guidelines. Diagnostics, 13:454, Jan 2023. URL: https://doi.org/10.3390/diagnostics13030454, doi:10.3390/diagnostics13030454. This article has 7 citations.
(pitman2012revisedinternationalconsensus pages 1-2): Martha Bishop Pitman. Revised international consensus guidelines for the management of patients with mucinous cysts. Cancer Cytopathology, 120:361-365, Dec 2012. URL: https://doi.org/10.1002/cncy.21235, doi:10.1002/cncy.21235. This article has 27 citations and is from a peer-reviewed journal.